Motif Neurotech receives FDA IDE approval for RESONATE depression BCI trial — blueberry-sized brain implant
Summary
Houston-based Motif Neurotech received FDA IDE approval in April 2026 for the RESONATE Early Feasibility Study, evaluating their DOT implant — a blueberry-sized wireless brain stimulator — for treatment-resistant depression. Delivered in a 20-minute outpatient procedure that does not require exposing brain tissue, DOT uses patented wireless power technology from Rice University. Motif is the fastest implantable BCI company to reach IDE approval with a novel device, achieving it in just 4 years from founding.
Why it matters
A wireless, blueberry-sized brain implant for depression delivered in 20 minutes outpatient — without exposing the brain — is a fundamentally different surgical proposition from DBS. If RESONATE shows efficacy, DOT could extend implantable neuromodulation for mental health to patients who would never accept the surgical burden of conventional DBS.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial